Comparison of Tumor Markers and Risk of Malignancy Index (RMI) in Borderline OvarianTumors Names of
Author:
Affiliation:
1. Istanbul Medeniyet University
2. Istanbul Goztepe Prof. Dr. Süleyman Yalcın City Hospital
3. Istanbul Gaziosmanpasa Education and research Hospital
Abstract
Background Borderline ovarian tumours (BOTs) are non-invasive tumours with low malignancy potential frequently observed in patients of reproductive age. Therefore, preoperative differential diagnosis is important in these patients. In our study, we tried to differentiate benign and borderline ovarian tumours preoperatively using risk of malignancy (RMI) index and tumour markers. Methods In our study, we retrospectively compared tumour markers and risk of malignancy index (RMI) of 85 patients aged between 17–84 years with postoperative benign (n:52) and borderline (n:33) ovarian cysts. Results In our study, the mean age of the benign group was significantly higher than the borderline group (p = 0.001). Ca 125 and RMI values were significantly higher in the borderline group compared to the benign group (p = 0.001 and p = 0.018). In addition, mucinous tumours had significantly larger tumour diameter than serous tumours in the borderline group (p = 0.022). Conclusion As a result of our study, since borderline ovarian tumours are seen in young patients of reproductive age, it may be suggested to use Ca125 and RMI for the differential diagnosis of benign and borderline cysts preoperatively.
Publisher
Springer Science and Business Media LLC
Reference25 articles.
1. Colombo N, ESMO-ESGO Ovarian Cancer Consensus Conference Working Group. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. Ann Oncol. 2019;30(5):672–705. 10.1093/annonc/mdz062.
2. Borderline ovarian tumors in Denmark 1997–2018: Time trends in incidence by histology, age and educational level;Baandrup L;Acta Obstet Gynecol Scand,2021
3. Organization (WHO) classification of female genital tumours introduced in the 5th edition (2020) McCluggage WG;Singh N;Histopathology,2022
4. Seromucinous and Mucinous Borderline Ovarian Tumors: We Need to Know More;Laban M;Reprod Sci,2023
5. Shazly S, Laughlin-Tommaso SK, Gynecology. A CREOG and Board Exam Review. Cham, Switzerland: Springer International Publishing; 2020. pp. 489–519.
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3